Αρχειοθήκη ιστολογίου

Αλέξανδρος Γ. Σφακιανάκης
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5
Άγιος Νικόλαος Κρήτη 72100
2841026182
6032607174

Κυριακή 30 Μαΐου 2021

The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies

xlomafota13 shared this article with you from Inoreader

SocialThumb.00008390.DC.jpeg

To review the current role of regional chemotherapy in the management of advanced limb melanoma. Articles reporting the results of isolated limb infusion (ILI) were identified by performing a comprehensive literature search using the PubMed database. Keywords included isolated limb infusion, in-transit me lanoma and melphalan. No publication date restrictions were applied. ILI data were compared with those from current systemic therapy clinical trials and the previously reviewed isolated limb perfusion (ILP) literature. Regional chemotherapy is today required in fewer patients because effective systemic therapies now provide an alternative treatment for those who develop extensive local melanoma recurrence or in-transit metastases (ITMs). However, regional chemotherapy may be a valuable treatment option when the side-effects of systemic therapies are of concern, or after systemic treatment failure. ILP achieves overall response rates (ORRs) of 64–100% and complete response rates (CRRs) of 25–89%. ILI achieves ORRs of 41–91% and CRRs of 6–39%. ILP and ILI can have a low risk of serious morbidity. Early results from treatment with ILP or ILI in conjunction with systemic immune therapies suggest that these modalities can be safely combined, which may be useful in patients with r efractory limb disease. Regional chemotherapy remains important in the armamentarium of clinicians managing patients with unresectable limb melanoma and may be preferable in those who are frail, elderly or who are at high risk from complications of systemic therapies. The efficacy of combining regional chemotherapy with systemic immune therapy is currently being assessed. Received 31 December 2020 Accepted 18 March 2021 Correspondence to John F. Thompson, MD, Melanoma Institute Australia, The University of Sydney, 40 Rocklands Rd, North Sydney, NSW 2060, Australia, Tel: +61 (0)2 9911 7366; fax: +61 (0)2 9954 9290; e-mail: john.thompson@melanoma.org.au Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου